Literature DB >> 9085628

Hepatotoxicity after a short course of low-dose pyrazinamide.

K A al Sarraf1, P P Michielsen, E I Hauben, A Lefebure, A M Ramon, E A Van Marck, P A Pelckmans.   

Abstract

We report on a patient who developed extensive centrolobular liver necrosis after a treatment with low-dose (25 mg/kg/d) pyrazinamide for only 4 weeks, combined with rifampicin, 600 mg/d). In the past, the patient already developed severe aminotransferase elevations under isoniazid treatment. After prompt withdrawal of the drugs, a gradual decline of the aminotransferases was observed. No signs of hepatic failure developed. Pyrazinamide has to be used with caution, even in low-dose, especially when combined with rifampicin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9085628

Source DB:  PubMed          Journal:  Acta Gastroenterol Belg        ISSN: 1784-3227            Impact factor:   1.316


  2 in total

1.  Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.

Authors:  Tina Papastavros; Lisa R Dolovich; Anne Holbrook; Lori Whitehead; Mark Loeb
Journal:  CMAJ       Date:  2002-07-23       Impact factor: 8.262

Review 2.  Hepatic safety of antibiotics used in primary care.

Authors:  Raúl J Andrade; Paul M Tulkens
Journal:  J Antimicrob Chemother       Date:  2011-05-17       Impact factor: 5.790

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.